Learn More
OBJECTIVES To assess the effects of rivastigmine on the core domains of Alzheimer's disease. DESIGN Prospective, randomised, multicentre, double blind, placebo controlled, parallel group trial. Patients received either placebo, 1-4 mg/day (lower dose) rivastigmine, or 6-12 mg/day (higher dose) rivastigmine. Doses were increased in one of two fixed dose(More)
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly(More)
OBJECTIVE To investigate whether or not a coding polymorphism in the cystatin C gene (CST3) contributes risk for AD. DESIGN A case-control genetic association study of a Caucasian dataset of 309 clinic- and community-based cases and 134 community-based controls. RESULTS The authors find a signficant interaction between the GG genotype of CST3 and(More)
In-vivo metabolic measures with positron emission tomography using (18)F-fluorodeoxyglucose (FDG-PET) have demonstrated hypometabolism in temporal, frontal, and hippocampal areas during the early stages of Alzheimer's disease (AD). Progression of the dementia in AD involves compromised cholinergic functioning. Cholinesterase inhibitors have demonstrated(More)
We evaluated the efficacy and safety of the centrally acting cholinesterase inhibitor, rivastigmine tartrate, for patients with mild to moderately severe Alzheimer's disease (AD) with or without concurrent vascular risk factors (VRF). Patients (45-90 years of age) were randomized to placebo (n = 235), low-dose rivastigmine (1-4 mg/day, n = 233), or(More)
Cytochemistry was used to examine the distribution of two pathways of utilization of hydrogen (Type I and Type II H) generated by glucose-6-phosphate dehydrogenase (G6PD) in circumventricular organs (CVOs) and the hypothalamo-neurohypophysial system in cryostat sections of rat brain. Type I H is defined as that portion of the total reducing equivalents(More)
BACKGROUND Evidence suggests that disease severity predicts the response of patients with Alzheimer disease (AD) to cholinesterase inhibitor treatment, raising the question of whether disease progression also predicts response to this treatment. OBJECTIVE To evaluate retrospectively whether rate of disease progression during placebo treatment affects(More)
Temporal changes in tyrosine hydroxylase (TH) mRNA levels in medullary A1 and A2 neurons and locus coeruleus (LC) cells were studied 6, 12 and 24 h following orchidectomy in rats. Brains from intact controls and sham castrated rats also were evaluated at these same time periods. In situ hybridization histochemistry and quantitative image analysis techniques(More)
The Internet of Things (IoT) many be thought of as the availability of physical objects, or devices, on the Internet [1]. Given such an arrangement it is possible to access sensor data and control actuators remotely. Furthermore such data may be combined with data from other sources, e.g., with data that is contained in the Web and/or operated on by(More)
Abstract We examined the temporal changes in plasma luteinizing hormone (LH) levels, median eminence luteinizing hormone-releasing hormone (LHRH) concentrations and LHRH mRNA levels in estrogen-treated, ovariectomized rats with empty or antiestrogen- containing microcannulae stereotaxically implanted into the medial preoptic area. Neither treatment(More)